Merck (MRK.N) said it has commercially launched in China the world’s first
single fixed‑dose long‑acting RSV monoclonal antibody for prevention of
RSV‑caused lower respiratory tract infection in newborns and infants entering or
born into their first RSV season. The product is administered as a single fixed
dose without weight‑based dosing.